KURA News and Press, Kura Oncology Inc. From 02/24/22

Kura Oncology press release (NASDAQ:KURA): Q4 GAAP EPS of -$0.49 beats by $0.05. Cash, cash equivalents and short-term investments totaled $518.0 million as of December 31, 2021, compared with $633.3 million as of December 31, 2020. For further details see: Kura Oncology GAAP EPS of -$0...

– Patient enrollment continues in KOMET-001 Phase 1b study of ziftomenib (KO-539) in AML – – Multiple milestones and data readouts from KOMET-001 expected in 2022 – – First patients dosed in Phase 1/2 study of tipifarnib plus alpelisib in HNSCC &#x...

Kura Oncology (NASDAQ:KURA) is scheduled to announce Q4 earnings results on Thursday, February 24th, after market close. The consensus EPS Estimate is -$0.54 For further details see: Kura Oncology Q4 2021 Earnings Preview

SAN DIEGO, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report fourth quarter and full year 2021 financial ...

SAN DIEGO, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the 11 th Annual SVB Leerink Global Hea...

Palm Beach, FL – February 2, 2022 – FinancialNewsMedia.com News Commentary – In the battle against pancreatic cancer, new and innovative clinical trials have become extremely critical. These trials offer patients early access to cutting-edge treatments that ...

Kura Oncology (NASDAQ:KURA) said Marc Grasso will step down as CFO and chief business officer, effective Feb. 4. KURA has expanded its leadership team with 3 promotions: Mollie Leoni to senior VP, clinical development; Pete De Spain to senior VP, investor relations and corporate communication...

SAN DIEGO, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the expansion of its leadership team with three promotions: Moll...

– FDA lifts partial clinical hold following agreement on mitigation strategy for differentiation syndrome – – KOMET-001 study to resume screening and enrollment of new patients – – Encouraging safety, tolerability and clinical activity observed amo...

Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...